You are here

MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation

Date
02/15/2024 Case Management Order No. 1 - Notice of Initial Organizational Conference and Related Preliminary Matters
04/23/2024 Case Management Order No. 3 - Appointment of Plaintiffs’ Committee
04/23/2024 Case Management Order No. 4 - Preservation Order
05/08/2024 Case Management Order No. 6 - Appointment of Plaintiff Leadership
06/10/2024 Case Management Order No. 8 - New Procedures for Pro Hac Vice Admission
06/25/2024 Case Management Order No. 9 - Privilege Logging
07/14/2024 Case Management Order No. 10 - Rule 502d Order
07/14/2024 Case Management Order No. 11 - Qualified Protective Order & Sealing Process Order
07/14/2024 Case Management Order No. 12 - Plaintiff Fact Sheets
07/14/2024 Case Management Order No. 13 - Dismissal of Certain Novo Nordisk Defendants
07/14/2024 Case Management Order No. 14 - Direct Filing Order
07/31/2024 Case Management Order No. 15 - ESI Protocol
07/31/2024 Case Management Order No. 16 - Special Master Appointment and Protocol
08/08/2024 Case Management Order No. 17 - Time and Expense Protocol and Common Benefit Funds
08/23/2024 Case Management Order No. 18 - Cross Cutting Issues 1 and 2
11/05/2024 Case Management Order No. 21 - Amended Scheduling Order for Cross Cutting Issue No. 1
11/26/2024 Scheduling Order – 2025 Monthly Conferences
12/03/2024 Case Management Order No. 22 - Scheduling Order for Motions to Dismiss the Master Complaint
03/21/2025 Case Management Order No. 23 - Amended Scheduling Order for Cross Cutting Issue Nos. 2 and 3
03/21/2025 Case Management Order No. 24 - Deposition Protocol for Non-Experts
03/21/2025 Case Management Order No. 25 - Coordination Order
04/16/2025 Case Management Order No. 26 - Plaintiffs’ Production of ESI